Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: S&P Capital IQ – STARS Reports
$127.00
Provider: Pechala's Reports
$15.00
Provider: Pechala's Reports
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

GlaxosmithKline Plc receives FDA approval for Arnuity Ellipta (fluticasone furoate) in the US for the treatment of asthma


Wednesday, 20 Aug 2014 03:33pm EDT 

GlaxosmithKline Plc:Announced that the FDA has approved Arnuity Ellipta, a once-daily inhaled corticosteroid (ICS) medicine for maintenance treatment of asthma as prophylactic therapy in patients aged 12 years and older. Arnuity is not indicated for relief of acute bronchospasm.Approved doses are Arnuity Ellipta 100mcg and 200mcg.Arnuity Ellipta is administered once daily via the dry powder inhaler called Ellipta, which is also used across a range of other approved respiratory medicines in the GSK portfolio.